NCT01853748: A trial that was reported late by Dana-Farber Cancer Institute
This trial has reported, although it was 329 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01853748 |
|---|---|
| Title | A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 31, 2013 |
| Completion date | Aug. 26, 2019 |
| Required reporting date | Aug. 25, 2020, midnight |
| Actual reporting date | July 21, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 329 |